| Code | CSB-RA868278MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to NBL-012, targeting interleukin-23 subunit alpha (IL23A), also known as p19. IL23A combines with the p40 subunit to form the heterodimeric cytokine IL-23, which plays a critical role in inflammatory and immune responses by promoting the differentiation and maintenance of Th17 cells. IL-23 signaling is central to the pathogenesis of various autoimmune and inflammatory conditions, including psoriasis, psoriatic arthritis, inflammatory bowel disease, and ankylosing spondylitis. Dysregulated IL-23 activity contributes to chronic inflammation and tissue damage in these disorders.
NBL-012 represents a therapeutic antibody designed to selectively neutralize IL-23 by targeting its unique p19 subunit, distinguishing it from IL-12 which shares the p40 component. This biosimilar provides researchers with a valuable tool for investigating IL-23-mediated immune mechanisms, exploring inflammatory disease models, and studying Th17 cell biology. The antibody supports investigations into cytokine networks, autoimmune pathways, and potential therapeutic interventions targeting the IL-23/Th17 axis.
There are currently no reviews for this product.